A Randomized, Open-Label, Parallel-Group, Non-Inferiority Study Comparing Efficacy, Safety, And Tolerability Of Remibrutinib After Switching From Ocrelizumab In Participants Living With Relapsing Multiple Sclerosis, Followed By Open-Label Treatment With R
Posted Date: Apr 28, 2025
- Investigator: Aram Zabeti
- Specialties:
- Type of Study: Drug
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib
Criteria:
Null
Keywords:
Remibrutinib, Ocrelizumab, Relapsing Multiple Sclerosis
For More Information:
Tiffany Rupert
NULL
tiffany.rupert@uc.edu